相关实验视频

Updated: Jun 30, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

急性髓性白血病分化治疗的进展:一个批判性审查

Amal Kamal Abdel-Aziz¹

¹Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt; Smart Health Initiative, Biological and Environmental Sciences and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal 23955, Saudia Arabia.

Biochemical pharmacology

|July 28, 2023

概括

差异化剂对急性髓性白血病 (AML) 治疗有希望,但需要组合治疗方案. 仅仅针对白血病发起细胞是不够的,因为AML细胞的可塑性.

科学领域:

血液学血液学血液学
在瘤学瘤学.
癌症生物学癌症生物学

背景情况:

急性骨髓性白血病 (AML) 涉及到骨髓原体分化和扩散的受损.
传统的分化剂在非APLAML中经常失败,导致耐药性疾病或复发.
癌症干细胞模型表明白血病发起细胞驱动复发,但成熟的AML细胞也表现出可塑性.

研究的目的:

批判性地审查AML治疗中差异化剂的潜力和挑战.
讨论从传统和新型差异化剂中学到的经验教训.
强调需要针对所有AML细胞状态的组合策略.

主要方法:

关于AML中常规和新型区分剂的文献综述.
关于白血病发起细胞和成熟AML爆发性可塑性的证据分析.
对治疗策略和挑战进行批判性讨论.

主要成果:

大多数非APLAML患者是耐药或复发的,尽管有差异化药物治疗.
成熟的AML爆发具有去差异化可塑性和白血病产生潜力.
单单准白血病发起细胞可能不足以防止复发.

结论:

区分剂对AML有希望,但必须在组合疗法中使用.
组合疗法应该旨在消除AML细胞的所有成熟/分化状态.
免疫类型和形态分析可能低估了AML的真正负担.

关键词:

在AML,AML就是AML.没有分化,没有分化.在LSC的LSC上.复发复发的情况减免减免减免电阻电阻电阻电阻电阻电阻

更多相关视频

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...